Viyash Scientific Allots ESOP Shares to Employees

Viyash Scientific Limited announced on April 2, 2026, the approval for the allotment of 16,667 equity shares to eligible employees under its SeQuent ESOP 2020 scheme. The exercise price for these shares is set at ₹86 per equity share, with a face value of ₹2 per share. This corporate action will lead to a marginal increase in the company's total issued and paid-up equity share capital.

Why This Matters

Employee Stock Option Plans (ESOPs) are a common tool companies use to reward and retain talent. By offering shares at a predetermined price, companies aim to align employee interests with those of shareholders. This allotment reflects Viyash Scientific's commitment to employee participation in long-term value creation.

Company Background

Viyash Scientific Limited, formerly known as Sequent Scientific Limited, operates as an integrated pharmaceutical enterprise focusing on Animal Health, API, Human Health, and CDMO services. The company officially changed its name in January 2026 following a composite scheme of amalgamation.

Previous Allotments and Performance

This is not the first ESOP allotment under the SeQuent ESOP 2020 plan; the company has completed several similar allotments in recent months, including February and January 2026, all at the ₹86 exercise price. Recently, Viyash Scientific reported strong financial performance for Q3 FY26, its first quarter as a unified entity post-merger, with revenues of INR 858 crores and adjusted EBITDA of INR 185 crores.

Impact of the Allotment

The total number of outstanding equity shares will increase by 16,667. The company's issued and paid-up equity share capital will see a modest rise, reflecting the face value of the new shares. The newly allotted shares will rank pari passu, meaning they are on equal footing with existing equity shares.

Risks and Monitoring

No specific risks were identified for this particular share allotment event. Looking ahead, investors may track future ESOP grant cycles, employee retention rates, overall workforce morale, the company's continued integration and performance post-merger, and any further strategic initiatives announced by Viyash Scientific.

Competitive Landscape

Viyash Scientific operates in the pharmaceutical and animal health sectors. Its peers include major Indian pharmaceutical players like Sun Pharmaceutical Industries Ltd., Divi's Laboratories Ltd., and Torrent Pharmaceuticals Ltd. In the animal health segment, it competes with global entities such as Phibro Animal Health Corporation.